Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations Marcello Maugeri-SaccàMaddalena BarbaLuigi Di Lauro Review 13 August 2014 Pages: 227 - 235
Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review S. J. IoannidesP. L. BarlowD. Porter Review 14 August 2014 Pages: 237 - 248
Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs Amy PlotkinClaude-Henry VolmarDorraya El-Ashry Preclinical study 17 August 2014 Pages: 249 - 263
High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF-β-dependent epithelial-mesenchymal transition in breast cancer Cheng ZhangYong HanChengchao Shou Preclinical study 17 August 2014 Pages: 265 - 281
Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer Julie M. MaddenKelly L. MuellerJulie L. Boerner Preclinical study 17 August 2014 Pages: 283 - 293
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer Bharath RudrarajuMarjolein DroogCarlo Palmieri Preclinical study 22 August 2014 Pages: 295 - 309
Outcomes of solid palpable masses assessed as BI-RADS 3 or 4A: a retrospective review Stephanie K. PattersonColleen H. NealKuanwong Watcharotone Preclinical study 24 August 2014 Pages: 311 - 316
Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy Rei MimotoTadashi KobayashiHiroshi Takeyama Preclinical study 26 August 2014 Pages: 317 - 324
Circulating tumor cells in non-metastatic triple-negative breast cancer Mandar KarhadeCarolyn HallAnthony Lucci Preclinical Study Open access 28 August 2014 Pages: 325 - 333
Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate? David K. WoolfAnwar R. PadhaniAndreas Makris Clinical trial 17 August 2014 Pages: 335 - 343
Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer Andreas D. HartkopfDiana StefanescuFlorin-Andrei Taran Clinical trial 24 August 2014 Pages: 345 - 351
Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures Chi-Cheng HuangShih-Hsin TuEric Y. Chuang Clinical Trial 27 August 2014 Pages: 353 - 370
Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients Isabel T. RubioMartin Espinosa-BravoVicente Peg Clinical trial 28 August 2014 Pages: 371 - 380
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival Mala PandeMelissa L. BondyAbenaa M. Brewster Epidemiology 10 August 2014 Pages: 381 - 387
Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program Maegan V. PrummelSusan J. DoneAnna M. Chiarelli Epidemiology 10 August 2014 Pages: 389 - 399
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients T. ByrskiT. HuzarskiS. A. Narod Epidemiology 17 August 2014 Pages: 401 - 405
Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer Claudette FalatoJulie LorentTheodoros Foukakis Epidemiology 17 August 2014 Pages: 407 - 414
Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study E. H. AllottC.-K. TseM. A. Troester Epidemiology 24 August 2014 Pages: 415 - 421
Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells Yifang WeiXiaofeng LaiJian Zhang Brief Report 10 July 2014 Pages: 423 - 431
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer Vakaramoko DiabyGeorges AdunlinAlberto J. Montero Brief Report 11 July 2014 Pages: 433 - 441
Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer Vakaramoko DiabyGeorges AdunlinAlberto J. Montero Erratum 28 August 2014 Pages: 443 - 443
Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation Mary K. AskrenMisook JungBernadine Cimprich Brief Report 21 August 2014 Pages: 445 - 455
Unvalidated antibodies and misleading results David RimmKurt SchalperLajos Pusztai Letter to the Editor 03 August 2014 Pages: 457 - 458
Author’s response to “Letter to the editor: unvalidated antibodies and misleading results” S. MuenstA. TzankovS. D. Soysal Rebuttal Letter 01 August 2014 Pages: 459 - 462
